SAN DIEGO (June 8) – Kilpatrick Townsend & Stockton announced today that the Department of Veteran Affairs (VA) and, firm client, Rubicon Biotechnology, LLC have entered into an exclusive license agreement to practice U.S. Patent Application Serial No. 13/815,829 (anti-body-mediated transduction of heat shock proteins into living cells.). The deal closed on Wednesday, May 13, 2015, and is one of only about 15 direct exclusive license agreements the VA has completed in the past 8 years.

The Kilpatrick Townsend team was led by Kandace Watson, head of Kilpatrick Townsend's Patent and Technology License Practice in the Southwestern United States.

Rubicon Biotechnology is a privately held biotechnology company that develops targeted, life-saving technologies in the areas of defense countermeasures, cardiology, neurology and oncology. Rubicon has in-licensed two platform technologies for drug development. The first is “Antibody Mediated Transduction of Heat Shock Proteins into Living Cells” from the Veterans Administration. This technology delivers heat shock protein, a key protein which saves injured cells that suffer hypoxic and oxidative stresses that occur following unfortunately common tissue injuries, such as heart attack, stroke and traumatic brain injury. The second technology, “Modified Non-Internalizing A5 Variants," licensed from MosaMedix N.V., delivers immunostimulants to tumors in order to enhance the immune system’s ability to fight cancer. With support from several SBIR and CounterACT grants, and in collaboration with major institutions in the U.S., Rubicon is developing these targeted therapies with the goal of improving health outcomes and saving lives.

###